refinedBoundary: Summarize Primary and Refined Secondary Boundaries, Nominal...
In gsrsb: Group Sequential Refined Secondary Boundary
refinedBoundary R Documentation
Summarize Primary and Refined Secondary Boundaries, Nominal Significance
Description
Primary boundaries, refined secondary boundaries, and nominal significance for the secondary endpoint are listed.
Usage
refinedBoundary(
alpha,
tVec,
pOBF = TRUE,
sOBF = FALSE,
LanDeMets = FALSE,
digits = 2
)
Arguments
alpha
type I error probability.
tVec
vector of relative information levels. The last element in the vector is 1.
pOBF
type of primary boundary, TURE is the O'Brien-Fleming boundary, FALSE is the Pocock boundary.
sOBF
type of secondary boundary, TURE is the O'Brien-Fleming boundary, FALSE is the Pocock boundary.
LanDeMets
type of boundary, TRUE is the error spending approach, FALSE is the original approach.
digits
number of digits after decimal point for primary and secondary boundaries.
Details
This function gives a list including primary boundary, refined secondary boundary, and the nominal significance for the secondary endpoint.
The number of digits for the nominal significance depends on parameter alpha.
Value
a result list including primary boundary, refined secondary boundary, and the nominal significance for the secondary endpoint.
Author(s)
Jiangtao Gou
References
Glimm, E., Maurer, W., and Bretz, F. (2010). Hierarchical testing of multiple endpoints in group-sequential trials. Statistics in Medicine 29, 219-228.
Hung, H. M. J., Wang, S.-J., and O'Neill, R. (2007). Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. Journal of Biopharmaceutical Statistics 17, 1201-1210.
Jennison, C. and Turnbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC, New York.
Lan, K. K. G., and Demets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70, 659-663.
O'Brien, P. C., and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics 35, 549-556.
Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika 64, 191-199.
Tamhane, A. C., Mehta, C. R., and Liu, L. (2010). Testing a primary and a secondary endpoint in a group sequential design. Biometrics 66, 1174-1184.
Tamhane, A. C., Gou, J., Jennison, C., Mehta, C. R., and Curto, T. (2018). A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks. Biometrics, 74, 40-48
Examples
require(mvtnorm)
require(ldbounds)
result <- refinedBoundary(alpha=0.05,tVec=c(0.2,0.6,1))
result$primaryBoundary
result$secondaryBoundary
result$nomialSignificance
gsrsb documentation built on July 9, 2023, 6:02 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| refinedBoundary | R Documentation |
Summarize Primary and Refined Secondary Boundaries, Nominal Significance
Description
Primary boundaries, refined secondary boundaries, and nominal significance for the secondary endpoint are listed.
Usage
refinedBoundary(
alpha,
tVec,
pOBF = TRUE,
sOBF = FALSE,
LanDeMets = FALSE,
digits = 2
)
Arguments
alpha |
type I error probability. |
tVec |
vector of relative information levels. The last element in the vector is 1. |
pOBF |
type of primary boundary, |
sOBF |
type of secondary boundary, |
LanDeMets |
type of boundary, |
digits |
number of digits after decimal point for primary and secondary boundaries. |
Details
This function gives a list including primary boundary, refined secondary boundary, and the nominal significance for the secondary endpoint.
The number of digits for the nominal significance depends on parameter alpha.
Value
a result list including primary boundary, refined secondary boundary, and the nominal significance for the secondary endpoint.
Author(s)
Jiangtao Gou
References
Glimm, E., Maurer, W., and Bretz, F. (2010). Hierarchical testing of multiple endpoints in group-sequential trials. Statistics in Medicine 29, 219-228.
Hung, H. M. J., Wang, S.-J., and O'Neill, R. (2007). Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. Journal of Biopharmaceutical Statistics 17, 1201-1210.
Jennison, C. and Turnbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC, New York.
Lan, K. K. G., and Demets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70, 659-663.
O'Brien, P. C., and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics 35, 549-556.
Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika 64, 191-199.
Tamhane, A. C., Mehta, C. R., and Liu, L. (2010). Testing a primary and a secondary endpoint in a group sequential design. Biometrics 66, 1174-1184.
Tamhane, A. C., Gou, J., Jennison, C., Mehta, C. R., and Curto, T. (2018). A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks. Biometrics, 74, 40-48
Examples
require(mvtnorm)
require(ldbounds)
result <- refinedBoundary(alpha=0.05,tVec=c(0.2,0.6,1))
result$primaryBoundary
result$secondaryBoundary
result$nomialSignificance
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.